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uMMARY A 11vc attenuated mumps and trivalcnt incaslcs-rubella-mumps (IVIR^'I)
vaccines have been applicd to 887 and 148 children \\, ith various underlying
diseases at the \, accine clinic of OSal<a University Hospital between 1975 and 1985,
respectivcly. Clinical reactions after mumps vaccination occurred in only 7 chil-
dren (0.87, ) and thus, after MRM un. .innti. n in 28 child""n (197. ), but that
underlying diseases were ITot dcteriorated by either \, accination. Clinical follow
up study rcvcalcd that 2 of the 430 childrcit jinmunized witll mumps vaccine had
contracted thc diseasc during 7 year PCriod and 2 of the 123 children jinmunizcd
with LIRA{ \, accine had contracted clinical mumps or rubella dtiring 3 year period.
The scroconversion rates after mumps vaccination were 70% and 61% by the
hcmagglutination inhibition (Hl) test and neutralization (NT) test, rcspectively,
whi1.947, by th" nunre^.. nt antib, dy to in"inbinne antig", (FAMA) rest. Thus.
after A{Rl\I vaccination \VCrc 877, for measles, 96% for rubella by thc Hl test and
8970 for mumps by the FANIA test. Scrological follow up study revealed that
antibodies elicitcd by mumps vaccination were sustained without substantial dcclinc
for. at least 7 years,
These results suggest that a 11vc attenuated mumps and LIRA'I vaccines are safc
and effective in children with various underlying diseases.
INTRODUCTION
IVlumps is a common childhood disease. In
I To whom requests for reprints should be
addressed.
healthy children, it is usually mild but may
be complicated by meningitis, pancreatitis or
orchitis. In children with various underlying
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diseases such as those with acute leukemia,
nephrotic syndrome or epilepsy, it may be
severe (Henson at a1. , 1971; Rashid at al. ,
1977) or deteriorate their underlying diseases
(Herin ,t a1. , 1983). The"efore it ^h. uld b.
considered that prevention of these children
against mumps infection Is more important
than that of healthy children. However, there
are few reports that a live mumps vaccine was
administered to children with various under-
lying diseases, except those with acute leukemia
rep. rt, d by Twig. " at a1. (1981). \V.
andadministered a live attenuated mumps
trivalent measles-rubella-mumps (MRM) vac-
cines to these children in the outpatient
clinic of the Department of Pediatrics, Osaka
University Hospital between 1975 and 1985.
In this paper, we report clinical and serological
follow up studies of two vaccines applied in
these children.
Furthermore, it was recently reported that
occurred in lessseroconversion for mumps
than two thirds of the recipients of monovalent
mumps or lv'IRAl vaccine (Sugiura et al. ,
1982). This reason is considered to be due
to not only the insufficient jinmunogenicity of
mumps vaccine but low sensitivity of mumps
antibody determination. So, we applied here
more sensitive and simplified technique for
mumps antibody determination using fluores-
cent antibody to membrane antigen (FAATA)
method.
were Linder well-controlled conditions at the time of
vaccination. Before vaccination, the jinnlune status
of individuals \\, as checked b}, the following tests
skin-tests with pHA, PPD and vancella, assay of
antibody activities to these viruses and counts on
the number of white blood cells
2. Patc, ,res
The live mumps vaccine Lised was " Biken Urnbe
Am9 ", each dose of the vaccine contained approxi-
mately 5 XIO' TclD, , of attenuated mumps virus
it \\, as injected singly or in combination with live
attenuated measles " Biken CAM. 70 "vaccine
andjor live attenuated rubella ' ' Biken
Matsuura strain "
The MRM vaccine Lised \\, as trivalent ' ' Biken
AllRiVl \, accine (test lot 101) ". It contained 2.5 x
10' PFUjml of CAM-70 measles vi"us, 10' ' FFU!inI
of Matsutira rubella virus, 10'7 TclD, ,jinl of Urabe
Volumes of 0.5 inI of vaccine weremumps \, Irus
injected subcutaneously into each child
MATERIALS AND METHODS
I. Sti, dy pupil/"ti011
Children \\, ith various underlying diseases, includ-
ing neuromuscular, allergic, congenital heart, di-
gestive and renal diseases, congenital in alformations
and neoplasms have been treated in the outpatient
clinic of the Department of Pediatrics, Osaka
University Hospital. Children with no history, of
clinical infection and no antibody against mumps
virus \\, ere jinmunized witll live mumps vaccine and
those with no history, of clinical infection and no
antibody against each of the three viruses were
jinmunized with MRM vaccine. All the children
3 . Sei o10gic tests
The antibody response to mumps \, irtis \\, as
determined by hemagglLitination inhibition (Hl)
test, neutralization (NT) test and fluorescent anti-
body to membrane antigen (FAMA) test
The Hl test \\, as carried out as described by
Yamanishi at a1. (1970). Briefly, after removal of
non specific inhibitors by treatment \\, ith Kaolin
and chicl< cells, the Hl antibod}, titers of the speci-
mens \\. ere determined Lising 4 Linits of HA antigen
and a 0.5', suspension of clticl< red ceils
The NT test \\, as performed b}, cytopathic effect
(CPE) method or piaque reduction method. The
CPE method \\, as done in microplates using LLC-
ATK* cells as described b}, Yamanishi at a1. (1973)
Namely 0025 inI of serialIy two fold diluted serum
was mixed \\, Ith equal \, o1ume of antigen containing
about 100 TclD, , of mumps \, irus (it'Iiyake strain)
in each well on Coming fiat bottom microplates
After incubation for one ITour at 37 C, the mixture
was kept o\, ernigltt at + C. On the following day
0.1 in10f LLC-MK. cells (about 2xlO' cellsjO. I inI)
was added to the serum-antigen mixture. On the
6th or 7th day after incubation, the NT titer \\. as
taken as the highest initial dilution of serum which
completely inhibited appearance of CPE. The
piaque reduction method was done in Vero cells as
described by Sakat" at a1. (1984). B, ich},, fou"fold
serial dilutions of sera were mixed \\, ith mumps
\, accine
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virus (Briders strain) which was diluted to give 20
to 30 FFU per well. The mixture was Itept at
35 C for one hour and inDCulated into two wells,
each on 24. well (16-mm) Linbro plastic plates
On the 3rd or 4th day after incubation, the NT
titer was taken as the serum dilution catising So',
PIaqLie reduction.
The FAMA test was carried out as described by
Baba at a1. (1984). Namely, fresh monolayers of
Vero cells were infected with in Limps \, irus (Miyake
strain) at multiplicity of infection I FFUjcell. The
cultures were maintained for 48 h Lintil a CPE was
observed extensively. Then the monolayers were
beaded off into phosphate buffered saline (PBS)
and centrifuged at 1,000g for. 5 min. The super-
natant was discarded and the pelleted cells were
resuspended in medium (a mixture of equal volumes
of Eagles' MEM and 199 medium containing 10',
heat-in activated calf serum). Non infected cells,
prepared in a similar manner, were LISed as controls.
A1iquots of 0005 in I of test sera serial Iy diluted in
microtiter plates (U plates, Cooke Engineering)
were transferred to Terasaki tissue culture plates
(60 Hat bottom wells, Falcon) and incubated at
37 C for 30 min with an equal volume of mumps
virus infected cell suspension (about 8 xiO' cells)
in a humidified atmosphere. The plastic plates
were dipped into 180 in10f PBS to remove the super-
natant of the cells adhering to the bottom of the
plastic. The washed cells were incubated at 37 C
for another 30min with 0005ml per well of a
dilution of fluorescein-conjugated goat antisera to
heavy-chain human IgG (A"eloy Chemical Co. ).
The plates were dipped into PBS to remove the
remaining conjugates from the cells, and then the
cells were examined in a Nikon inverted fluore-
model TMD. As shown inscence microscope
Fig. I, fluorescent positive cells for antibody against
membrane antigens of cells infected with mumps
virus were seen as cells with bright fluorescent
FIGURE I. Fluorescent positive Veto cells for antibody against mumps virus membrane antigen ( x 300).
KANESAKi, T. at al. Line ,, 1117"ps and MRM zincc, '"es fit Diseased Child, e, ,
rings around their SLirface adhering to titc plates.
Setopositivity for. ntumps \, irus was defined lis
a titer of 21:4 in the NT and FAMA test and
a titer of 21 : 8 in the Hl test
The antibody response to measles and rubella
viruses were determined by the Hl tests, as reported
elsewhere (Ueda, 1971; Suzuki at a1. , 1973) and
seropositivity wars defined as a titer of 21 : 8.
RESULTS
4. Chill'cal 10/10tu Ico on uutci, !ees
I. GII}11'cal reactt'ONs ofter offcc, '"all'0"QLiestionnaircs were sent to parents of \, arccinces
Parents whose children received mumps \, arccine As shown in Table I, a total of 887 children
were asked whethei. there had been any cases of classified into 7 groups were jinmunized with
mumpsin their neighborhood, whether their children
mumps vaccine and a total of 148 children
had come in contact with cases of mumps, and
with AIRM vaccine. Clinical reactions after
whether their children had contracted mumps
mumps vaccination were observed only 7since being vnccinated. Parents whose children
children (0.8%) 2 to 3 weeks after vaccination.received MRM vaccine were asked whetlTer there
3 children had mild fever and 4 had slighthad been any cases of each of the three diseases in
swelling of the parotid glands. Those aftertheir nciglTborhood, whetlTcr their childreit ITad
AllRM vaccination occurred in 28 childrcncome in contact with cases of calcl\ of the three
TABLE I. Grouping of MM, /erb^ing of, teases and N, ,"16er of childrew recei"!}^ lzhe 711","lbs or MRM
offcci"e
diseases, and whetller tileir children ITad contracted
caclt of the three diseases since being \, arccinated
If their children had contracted any of the three
diseases, we ascertained its clinical course and
exteitt of exposure to tlle virus by interviewing
them when they attended our outpatient clinic
DISCnses of Ne, 7:0i, s or N"111 o1/11/3ti, /, Ir SJIS!'11/5
Epilepsy, Febrile convLilsion, flydroccph;11/15, Cerebral Palsy, Ccrcbcll:Ir
ataxia, MuscLilar dystrophy, Myasthenia gravis etc
1,111,111"o10gic"/ or and, gi'c DISCns"s
Asthma, Atopic dermatitis, Egg allergy, Mill< allcrgy, Urtictii'in, 1<:1\\, a-
salti Diseases, Againmaglobulinemiti etc
Collg, nit"/ Heo, I Dr'seuses
VentricLilar septal defects, Atrial septal deftcts, Tetralogy, of Fallot,
Single \, entriclc, Transposition of the great arteries etc
DISCttses of the Dikes tit^e Syste, ,I or Kid, ICJ,
Hepatitis, Intractable diarrhea, Hirschspi. ung diseases, Congenitnl
billary at resia, Lymphoid hyper piasia, Nephrotic syndrome, GIDmcrLi-
lonephritis etc.
DISCt, ses of Malljii", ICt'es
Acute leukemia, Malignant lymphoma, 1<etinoblastomn, Neuroblastoma,
Wilms tumor, Yoll< sac tumor, Hepatoblastoma, Brain tumor etc
Diseases of the Endocrine Syste, ,, or Co, ,gelii!a! Ab, ,on"afities
Congenital adrenal ITypcrplasia, Hypothyroidism, Diabetes Mellitus,
Addison diseases, Glycogen storage diseases, Mucopolysaccharidosis,
Down syndrome, 18 trisomy syndrome etc
Healthy children
Total
Grouping of tinderlying diseases
Number of children receiving
live mumps or MRM vaccine
in Limps \, accine MRM vaccine
289 29















(19%) with differ. .nt undulying dts""^"^ 5 to
12 days after vaccination. Twenty-fom. of
the 28 children had moderate fever (tempera-
ture of 238 C) and 4 had sporadic rash with
moderate fever. No other clinical reaction
was observed. The incidence of them seemed
to be equal in each group. I\loreovcr, in all
the children who had them after either vac-
cination, their underlying diseases were not
deteriorated by it
2. C/ill, 'err/10/10?0 1115 31Ndy 4/1"' offcc, }tall'ON
Clinical follow up study after mumps vac-
cination is shown in Table 2. Answers were
received to 430 of the 887 questionnaires and
divided into 3 groups according to the extent
of exposure. There were only 2 cases of
mumps during the 7 year period. Among 428
vaccinees who had not contracted mumps,
103 vaccinecs had come in contact with cases
of mump^ (Group I), 70 had onc, urinered
mumps epidemics in their neighborhood
T'ABLE 2. Clinical 10/10t0 141> I to 7 yettrs dier
111M, ,!ps uricc!, I"tjo"
contact group
U epidemic group




(Group 11) and 255 had not come in contact
with cases of mumps nor had they encountered
mumps epidemics in their ncighborhood
(G". up 111).
2 cases who contracted clinical mumps after
vaccination developed the disease with mild
fever and slight swelling of the parotid glands.
Their underlying diseases were asthma and
congenital heart disease. Blood samples werc
taken from 2 cases be forc and after varccina-
No. of
answers


































FIGURE 2. Serological analysis of two cases \vlTo contracted clinical mumps after being vaccinated.









































tion, and after contraction. Antibody titers
of these sera were measured by the Hl, NT
and FAMA test.
As shown in Figure 2, serological analysis
revealed that case I contracted mumps because
he had not acquired immunity after vaccina-
tion and that case 2 contracted the disease
because he had acquired immunity one month
after vaccination but lost it 5 years later.
Clinical follow up study after MRM vac-
cination is shown in Table 3. Answers were
received to 123 of the 148 questionnaires.
There were only 2 cases of clinical infection
during the 3 year period although the number
of contact andlor epidemic cases was small.
One child whose underlying disease
asthma contracted clinical rubella with mild
fever and generalized eruption when there was
epidemics in her neighborhood. Another
child whose underlying disease was yolk sac
tumor contracted clinical mumps with mild
fever and moderate swelling of the parotid
glands two weeks after his sister developing
the disease.
Blood samples were not taken from 2 cases




TABLE 4. Antibody response 4 to 6 toeeks ofter
ad?nilzzitration of MMmps odect}Ie in 118 chzldre"







it geometric mean titers In all vaccinees
" NT test \\, as carried out by CPE nTethod
Seroconversion
rate (%)
TABLE 5. Hittz'body yespo"se 6 toeeks 4/1er










3. AMI!'body response offer Dorci', Jail'o11
Antibody response after mumps vaccina-
tion is shown in Table 4. Blood samples were
drawn from 118 of the 428 children who had
not contracted clinical mumps after being
vaccinated, 4 to 6 weeks after vaccination and
measured by the FAMA, Hl and NT tests.




it geometric mean titers in all \, accinees
" antibody responses to measles and rubella viruses
were determined by the Hl test
" antibody response to mumps virus was determined







were highest in the FAMA test. Seven
seronegative samples measured by the FAMA
test were obtained from the children with
againmaglobulinemia and acute leukemia.
Therefore, except for these jinmunologically
abnormal children, the seroconversion rate
was 100% by the FAMA tcst.
Antibody response after MRM vaccination
is shown in Table 5. Blood samples were
taken from 124 of the 148 children 6 weeks
after vaccination and measured by the Hl
and FAAIA tests. The seroconversion rates
to measles and mumps viruses were approxi-
mately 9070 and those to rubella virus were
969'0.
+. Serologica1 10/10to "p study ofter JIM"!lbs
ticCCl"at10n
Serological follow ups were made on the
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TABLE 6.
"accz'?rated











" NT test \\, as carried out by CPE nTethod




mumps after vaccination. According to the
results of clinical follow-ups as shown in Table
2, sequential serum samples taken from these
andchildren were divided into 3 groups
measured by the FAMA, Hl and NT tests
(T^b1,6). In coch g". up, co. h antib. dy titer
4 to 6 weeks after vaccination was not signifi-
cantly different from that I to 2 years after
vaccination and that 2 to 7 years after vaccina-
tion (p<0.05). Therefore, it became clear
that the FANIA, NT and Hl antibody titers
were retained without substantial decline for
at least 7 years'
Moreover between three groups, there was
no significant difference in each antibody titer
4 to 6 weeks, I to 2 years and 2 to 7 years after
vaccination, respectively (p<005). So, it
was considered that some of children of Group
111 whose parents reported that there had
been no contacts and no epidemics had actually

























inura at a1. (1973). Clinical and serological
follow up studies on these children were also
carried out by them (Yamanishi at a1. , 1971 ;
ISOmura et a1. , 1976), \vhiclt revealed that
protective efficacy, of the vaccine was excellent
and the Hl and NT antibody, titers were
retained without substantial decrease for at
least 4 years.
On the basis of these results, we adminis-
tered live mumps vaccine to children with
various underlying diseases as shown in Table
I, since 1975. A total of 887 children received
the vaccine up to 1983. Clinical reactions
after vaccination occurred in only 7 children
(0.89'0) without severe symptoms. This rate
similar to that in healthy children.
Nioreover, vaccination gave no Influence on
their underlying diseases. Clinical and sero-
logical follow up studies after vaccination, as
shown in Table 2 and Table 5, revealed that
the protective efficacy of the vaccine was
excellent and antibodies elicited by vaccination
persisted for at least 7 years without sub-
stantial decline in these children.
From these observations, we conclude that
a live mumps vaccine was applicable in chil-
dren witl\ \, arious underlying diseases and












The safety and high jinmunogenicity of live
attenuated " Biken mumps vaccine ", which
was administered to healthy children, were
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The effectiveness and safety of the IVIRM
vaccine have been well documented in foreign
countries (Buynak et a1. , 1969 ; Sinorodintsev
at a1. , 1970; Stokes at a1. , 1971). In our
country, Minekawa at a1. (1974) reported the
effects of various proportions of measles,
rubella and mumps vaccines to determine the
quantities in trivalent vaccine required to jin-
inunize children effectiveIy. Recently, Sugi-
ura at a1. (1982) reported the result of a field
trial of the MRM vaccine.
These reports indicated that the observed
antibody response and clinical reactions were
similar to those following vaccinations with
each vaccine alone. So, applied the
MRM vaccine in children with various under-
lying diseases since 1983 as shown in Table I.
A total of 148 children received the vaccine
up to 1985.
Clinical reactions after vaccination were
observed 26 children (19%) without severe
reactions. This rate was less than that in
healthy children (25,670) receiving the same
lot vaccine as reported by Kakiuchi et al.
(1985). Moreover, their underlying diseases
were stable after vaccination. The antibody
response and protective efficacy following
vaccination were excellent, as shown in Table
3 and Table 5. Therefore, we consider that
MRA!I vaccine was useful for prevention of the
three diseases in children with various under-
lying diseases when applied under careful
observations.
Finally, as the protective efficacy against
mumps infection after monovalent mumps or
MRM vaccination was excellent, the low sero-
conversion rate for mumps after either vaccina-
tion as reported by Sugiura et a1. (1982) was
considered to be due to the insensitivity of
antibody tests to mumps virus Nowadays
enzyme-linked jinmunosorbent assay (ELISA)
is being available as a rapid and sensitive test
to determine the antibody response after
vaccination (Sakata at at. , 1984). However,
there remain some problems on the method for
antigen preparations and reproducibility of
the tests. So, we introduced the FAMA test
in this study as a sensitive and simplified test
to determine the antibody response after vac-
cmation. As shown in Table 4, the serocon-
version rates measured by the Hl test and NT
test were 70% and 61%, respectively, while
those measured by the FAAIA test were 94% .
As reported previously (Kanesaki et a1. , 1985),
the sensitivity of this test was almost similar
to that of ELISA. Moreover, we could sim-
PIify the test using Terasaki tissue culture
plates and inverted microscope as reported
by Baba et a1. (1984). Therefore, we consider
that the FAMA test is one of the useful
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